Transcode Therapeutics (RNAZ) Total Non-Current Liabilities (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Total Non-Current Liabilities came in at $7.3 million in Q1 2026, up 1753.35% YoY from $392000.0 in Q1 2025, and up 3.43% on a QoQ basis from $7.0 million in Q4 2025.
Transcode Therapeutics (RNAZ) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Total Non-Current Liabilities data on file, last reported at $7.3 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 1753.35% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 1753.35% YoY) and the FY2025 annual result came in at $7.0 million, up 7.38% from the prior year.
- Total Non-Current Liabilities improved to $7.3 million in Q1 2026, from $7.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $7.3 million in Q1 2026 to a low of $38291.0 in Q4 2023.
- A 4-year average of $3.2 million and a median of $832875.0 in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 16983.38% — and 2025, when it increased 7.38%.
- Tracing RNAZ's Total Non-Current Liabilities over 4 years: stood at $38291.0 in 2023, then surged by 16983.38% to $6.5 million in 2024, then increased by 7.38% to $7.0 million in 2025, then advanced by 3.43% to $7.3 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $7.3 million (Q1 2026), $7.0 million (Q4 2025), and $832875.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 7.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.27 Mn |
| Dec 31, 2025 | 7.02 Mn |
| Sep 30, 2025 | 832,875.00 |
| Jun 30, 2025 | 553,714.00 |
| Mar 31, 2025 | 392,000.00 |
| Dec 31, 2024 | 6.54 Mn |
| Dec 31, 2023 | 38,291.00 |
| Dec 31, 2021 | 2.53 Mn |
| Jun 30, 2021 | 3.91 Mn |
| Dec 31, 2020 | 4.06 Mn |